Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q3 Report 2022

December 1, 2022

Q2 Report 2022

August 17, 2022

Q1 Report 2022

May 17, 2022

Investor presentations

HCW Presentation September 13, 2021

Canaccord Presentation August 12, 2021

Wedbush Presentation August 11, 2021

HCW Presentation March 9, 2021

SVB Leerink Presentation Feb 24, 2021

JPM Presentation Jan 14, 2021

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

1 2 3

Press Releases

ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares

press release

December 9, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 –…

Read more

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

press release

December 1, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1, 2022 –…

Read more

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

press release

November 22, 2022

Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of…

Read more
1 2 3 80

General Meetings

ObsEva Annual General Meeting 2020

June 9, 2020

Read more

ObsEva Annual General Meeting 2019

May 8, 2019

Read more
1 2 3 4

Upcoming Events

Year End 2022 Financial Results week of 06 March 2023

Event


    Read more
     

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    Media

    Katja Bührer

    +1 (917)-969-3438

    katja.buhrer@obseva.com

    Investor relations


    .


    Katja Bührer

    +1 (917)-969-3438

    katja.buhrer@obseva.com

    Clinical studies




    clinicaltrials@obseva.ch

    HR Office

    Charlotte Cadoux


    charlotte.cadoux@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    shauna.dillon@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue